You are here

  • Home
  • Archive
  • Volume 20, Issue 4
  • Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding
  1. Dimitrios Alexopoulos
  1. Patras University Hospital, Patras, Greece
  1. Correspondence to : Dr Dimitrios Alexopoulos, Patras University Hospital, Rio, Patras 26500, Greece; dalex{at}med.upatras.gr

https://doi.org/10.1136/ebmed-2015-110213

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Bonaca MP, Bhatt DL, Cohen M, et al., PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–800.OpenUrlCrossRefPubMed

    Context

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist constitute the cornerstone of treatment in patients with acute coronary syndrome (ACS) with a recommended duration of 1 year.1 Nevertheless, high rates of atherothrombotic events, for which platelet activation is heavily implicated, still occur at later stages.2 Therefore, a longer duration of DAPT appears intuitive, albeit with bleeding and cost-effectiveness issues being of particular concern.

    Methods

    This was a randomised, double-blind, placebo controlled, multinational trial involving patients >50 years old, …

    View Full Text

    Footnotes

    • Competing interests DA has received speaker honoraria from AstraZeneca and advisory board fees from AstraZeneca, Boeringer Ingelheim, Bayer and the Medicines Company.

    • Provenance and peer review Commissioned; internally peer reviewed.